RobertJanssenMD

Neurology • Berkeley, CA

Physician

Join to view full profile

Dr. Janssen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Janssen's full profile

Already have an account?

Office
2929 Seventh St
Suite 100
Berkeley, CA 94710
Phone+1 510-665-0414

Education & Training

University of Pennsylvania Health SystemResidency, Neurology, 1979 - 1985
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1978 - 1979
Keck School of Medicine of the University of Southern CaliforniaClass of 1978

Certifications & Licensure

GA State Medical License 1989 - 2025
American Board of Psychiatry and Neurology Neurology

Publications & Presentations

PubMed

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.
Peter Richmond, Terry Nolan, Anthony McGirr, Fiona Napier-Flood, Joshua Kim
Vaccine. 2024-10-24
4 citations
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Matthias Girndt, Patricia Houser, Roberto Manllo-Karim, John E Ervin, Chaim Charytan
Vaccine. 2023-05-11
22 citations
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controll...
Julio Torales, Osmar Cuenca-Torres, Laurentino Barrios, Luis Armoa-Garcia, Gladys Estigarribia
Vaccine. 2023-01-04

Press Mentions

Dynavax Technologies (DVAX) Q2 2020 Earnings Call TranscriptAugust 7th, 2020
Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing HemodialysisApril 28th, 2020
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (Pembrolizumab); Data Presented Today at the 2019 ASCO Annual MeetingJune 3rd, 2019
Join now to see all